Opinion|Videos|July 22, 2024
Is Clearance of ctDNA an Acceptable Surrogate End Point?
Author(s)Stacey A. Cohen, MD, Daniel H. Ahn, DO
Medical oncologists discuss whether ctDNA clearance can serve as an acceptable surrogate end point in the treatment of patients with colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
2
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
3
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
4
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
5